Amarin | AMRN - Sales Revenues

Stock Price
14.86
Daily Change
-0.66 -4.25%
Monthly
-5.47%
Yearly
61.52%
Q1 Forecast
14.88

Amarin reported $49.67M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.91B 144M Sep/2025